227 related articles for article (PubMed ID: 20362020)
1. Downregulation of EGFR by a novel multivalent nanobody-liposome platform.
Oliveira S; Schiffelers RM; van der Veeken J; van der Meel R; Vongpromek R; van Bergen En Henegouwen PM; Storm G; Roovers RC
J Control Release; 2010 Jul; 145(2):165-75. PubMed ID: 20362020
[TBL] [Abstract][Full Text] [Related]
2. Sym004: a novel synergistic anti-epidermal growth factor receptor antibody mixture with superior anticancer efficacy.
Pedersen MW; Jacobsen HJ; Koefoed K; Hey A; Pyke C; Haurum JS; Kragh M
Cancer Res; 2010 Jan; 70(2):588-97. PubMed ID: 20068188
[TBL] [Abstract][Full Text] [Related]
3. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
[TBL] [Abstract][Full Text] [Related]
4. Tumor-targeted Nanobullets: Anti-EGFR nanobody-liposomes loaded with anti-IGF-1R kinase inhibitor for cancer treatment.
van der Meel R; Oliveira S; Altintas I; Haselberg R; van der Veeken J; Roovers RC; van Bergen en Henegouwen PM; Storm G; Hennink WE; Schiffelers RM; Kok RJ
J Control Release; 2012 Apr; 159(2):281-9. PubMed ID: 22227023
[TBL] [Abstract][Full Text] [Related]
5. Anti-tumor activity of monoclonal antibody CIBCNSH3 generated to the human EGF receptor.
Udayachander M; Dean CJ; Meenakshi AN; Sivakumar N; Babu PB; Sivakumar J
Hum Antibodies; 1997; 8(2):60-4. PubMed ID: 9289389
[TBL] [Abstract][Full Text] [Related]
6. Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: implications for the mechanisms of action.
Lammerts van Bueren JJ; Bleeker WK; Bøgh HO; Houtkamp M; Schuurman J; van de Winkel JG; Parren PW
Cancer Res; 2006 Aug; 66(15):7630-8. PubMed ID: 16885363
[TBL] [Abstract][Full Text] [Related]
7. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
8. Effect of the anti-receptor ligand-blocking 225 monoclonal antibody on EGF receptor endocytosis and sorting.
Jaramillo ML; Leon Z; Grothe S; Paul-Roc B; Abulrob A; O'Connor McCourt M
Exp Cell Res; 2006 Sep; 312(15):2778-90. PubMed ID: 16806168
[TBL] [Abstract][Full Text] [Related]
9. Differentiation or immune destruction: two pathways for therapy of squamous cell carcinomas with antibodies to the epidermal growth factor receptor.
Modjtahedi H; Eccles S; Sandle J; Box G; Titley J; Dean C
Cancer Res; 1994 Apr; 54(7):1695-701. PubMed ID: 8137284
[TBL] [Abstract][Full Text] [Related]
10. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
11. Carcinomas unresponsive to either cisplatinum or anti-EGFR therapy can be growth inhibited by combination therapy of both agents.
Knecht R; Peters S; Adunka O; Strebhardt K; Gstoettner W; Hambek M
Anticancer Res; 2003; 23(3B):2577-83. PubMed ID: 12894544
[TBL] [Abstract][Full Text] [Related]
12. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma.
Thomas SM; Bhola NE; Zhang Q; Contrucci SC; Wentzel AL; Freilino ML; Gooding WE; Siegfried JM; Chan DC; Grandis JR
Cancer Res; 2006 Dec; 66(24):11831-9. PubMed ID: 17178880
[TBL] [Abstract][Full Text] [Related]
13. Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy.
Hambek M; Solbach C; Schnuerch HG; Roller M; Stegmueller M; Sterner-Kock A; Kiefer J; Knecht R
Cancer Res; 2001 Feb; 61(3):1045-9. PubMed ID: 11221831
[TBL] [Abstract][Full Text] [Related]
14. Nanobody-albumin nanoparticles (NANAPs) for the delivery of a multikinase inhibitor 17864 to EGFR overexpressing tumor cells.
Altintas I; Heukers R; van der Meel R; Lacombe M; Amidi M; van Bergen En Henegouwen PM; Hennink WE; Schiffelers RM; Kok RJ
J Control Release; 2013 Jan; 165(2):110-8. PubMed ID: 23159529
[TBL] [Abstract][Full Text] [Related]
15. Insulin-like growth factor receptor as a therapeutic target in head and neck cancer.
Barnes CJ; Ohshiro K; Rayala SK; El-Naggar AK; Kumar R
Clin Cancer Res; 2007 Jul; 13(14):4291-9. PubMed ID: 17634559
[TBL] [Abstract][Full Text] [Related]
16. Blockade of epidermal growth factor receptor function by bivalent and monovalent fragments of 225 anti-epidermal growth factor receptor monoclonal antibodies.
Fan Z; Masui H; Altas I; Mendelsohn J
Cancer Res; 1993 Sep; 53(18):4322-8. PubMed ID: 8364927
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells.
O-charoenrat P; Modjtahedi H; Rhys-Evans P; Court WJ; Box GM; Eccles SA
Cancer Res; 2000 Feb; 60(4):1121-8. PubMed ID: 10706134
[TBL] [Abstract][Full Text] [Related]
18. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
[TBL] [Abstract][Full Text] [Related]
19. Amlodipine, a Ca2+ channel blocker, suppresses phosphorylation of epidermal growth factor receptor in human epidermoid carcinoma A431 cells.
Yoshida J; Ishibashi T; Yang M; Nishio M
Life Sci; 2010 Jan; 86(3-4):124-32. PubMed ID: 19951711
[TBL] [Abstract][Full Text] [Related]
20. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
